Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Valproate sodium [USAN:USP]
RN: 1069-66-5
UNII: 5VOM6GYJ0D
InChIKey: AEQFSUDEHCCHBT-UHFFFAOYSA-M

Note

  • A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of voltage dependent sodium channels.

Molecular Formulas

  • C8-H15-Na-O2
  • C8-H15-O2.Na
  • C8-H16-O2.Na

Molecular Weight

  • 166.1945
 

Classification Codes

  • Anticonvulsant
  • Drug / Therapeutic Agent
  • Human Data
  • Mutation Data
  • Reproductive Effect

Names and Synonyms

Name of Substance

  • Valproate sodium [USAN:USP]

Synonyms

  • 2-Propylpentanoic acid sodium salt
  • 2-Propylvaleric acid sodium salt
  • Abbott 44090
  • Convulex
  • Depacon
  • Depakene
  • Dipropylacetate sodium
  • EINECS 213-961-8
  • Epilim
  • Eurekene
  • KW 6066N
  • Labazene
  • Natrium valproat
  • Orfiril
  • Pentanoic acid, 2-propyl-, sodium salt
  • Sodium 2-n-propyl-pentanoate
  • Sodium 2-propylpentanoate
  • Sodium 2-propylvalerate
  • Sodium bispropylacetate
  • Sodium dipropylacetate
  • Sodium n-dipropylacetate
  • Sodium valproate
  • UNII-5VOM6GYJ0D
  • Valerin
  • Valproate sodium
  • Valproic acid sodium salt
  • Valproic acid sodium salt (1:1)
  • Valproinsaeure, natrium

Systematic Names

  • Pentanoic acid, 2-propyl-, sodium salt
  • Sodium valproate
  • Valeric acid, 2-propyl-, sodium salt

Registry Numbers

CAS Registry Number

  • 1069-66-5

FDA UNII

  • 5VOM6GYJ0D

System Generated Number

  • 0001069665

Molecular Formulas

Molecular Formulas

  • C8-H15-Na-O2
  • C8-H15-O2.Na
  • C8-H16-O2.Na

Molecular Formula Fragments

  • C8-H15-O2
  • C8-H16-O2
  • COMPONENT
  • Na

Structure Descriptors

InChI

1S/C8H16O2.Na/c1-3-5-7(6-4-2)8(9)10;/h7H,3-6H2,1-2H3,(H,9,10);/q;+1/p-1

InChIKey

AEQFSUDEHCCHBT-UHFFFAOYSA-M

Smiles

C(CCC)(CCC)C(=O)[O-].[Na+]

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
cat LD50 intraperitoneal 565mg/kg (565mg/kg)   Drugs. International Journal of Current Therapeutics and Applied Pharmacology Reviews. Vol. 13, Pg. 81, 1977.
child LDLo oral 750mg/kg (750mg/kg) LUNGS, THORAX, OR RESPIRATION: DYSPNEA

CARDIAC: OTHER CHANGES

BEHAVIORAL: COMA
Lancet. Vol. 1, Pg. 221, 1984.
child TDLo oral 1820mg/kg/12W (1820mg/kg) BEHAVIORAL: SLEEP

GASTROINTESTINAL: NAUSEA OR VOMITING
Lancet. Vol. 2, Pg. 1110, 1980.
dog LD50 intraperitoneal 700mg/kg (700mg/kg) BEHAVIORAL: TREMOR

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ATAXIA
Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
dog LD50 oral 1420mg/kg (1420mg/kg) BEHAVIORAL: TREMOR

GASTROINTESTINAL: NAUSEA OR VOMITING

BEHAVIORAL: ATAXIA
Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
guinea pig LD50 oral 824mg/kg (824mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ATAXIA

BEHAVIORAL: TREMOR
Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
hamster LD50 oral 1740mg/kg (1740mg/kg) BEHAVIORAL: TREMOR

BEHAVIORAL: ATAXIA

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
infant LDLo oral 250mg/kg/10D- (250mg/kg) GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF ENDOCRINE PANCREAS

BLOOD: HEMORRHAGE
Archives of Disease in Childhood. Vol. 58, Pg. 543, 1983.
man TDLo oral 17mg/kg (17mg/kg) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)

BRAIN AND COVERINGS: OTHER DEGENERATIVE CHANGES

LIVER: LIVER FUNCTION TESTS IMPAIRED
Journal of Toxicology, Clinical Toxicology. Vol. 30, Pg. 209, 1992.
man TDLo oral 214mg/kg/30D- (214mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" Israel Journal of Medical Sciences. Vol. 30, Pg. 283, 1994.
mouse LD50 intramuscular 832mg/kg (832mg/kg)   Biochemical Pharmacology. Vol. 22, Pg. 1701, 1973.
mouse LD50 intraperitoneal 470mg/kg (470mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: TREMOR

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
mouse LD50 intravenous 750mg/kg (750mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: TREMOR
Arzneimittel-Forschung. Drug Research. Vol. 26, Pg. 299, 1976.
mouse LD50 oral 977mg/kg (977mg/kg)   European Journal of Medicinal Chemistry--Chimie Therapeutique. Vol. 25, Pg. 71, 1990.
mouse LD50 subcutaneous 860mg/kg (860mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: TREMOR

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
mouse LD50 unreported 1700mg/kg (1700mg/kg)   United States Patent Document. Vol. #3301754,
rabbit LD50 intraperitoneal 1200mg/kg (1200mg/kg)   Drugs. International Journal of Current Therapeutics and Applied Pharmacology Reviews. Vol. 13, Pg. 81, 1977.
rabbit LD50 oral 1468mg/kg (1468mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 5, Pg. 41, 1971.
rat LD50 intraperitoneal 970mg/kg (970mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

BEHAVIORAL: ATAXIA

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 58, 1979.
rat LD50 intravenous 509mg/kg (509mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 33, Pg. 1155, 1983.
rat LD50 oral 670mg/kg (670mg/kg)   British Journal of Pharmacology. Vol. 74, Pg. 957P, 1981.
rat LD50 subcutaneous 1029mg/kg (1029mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 5, Pg. 41, 1971.
women TDLo oral 500mg/kg (500mg/kg) BEHAVIORAL: MUSCLE WEAKNESS

BEHAVIORAL: SLEEP
Postgraduate Medical Journal. Vol. 62, Pg. 409, 1986.
women TDLo oral 1040mg/kg (1040mg/kg) BLOOD: THROMBOCYTOPENIA

BEHAVIORAL: COMA

BRAIN AND COVERINGS: CHANGES IN SURFACE EEG
Journal of Toxicology, Clinical Toxicology. Vol. 33, Pg. 279, 1995.